Lifecore Biomedical, Inc. (NASDAQ:LFCR) Major Shareholder Aron R. English Sells 96,137 Shares

Lifecore Biomedical, Inc. (NASDAQ:LFCR - Get Free Report) major shareholder Aron R. English sold 96,137 shares of the business's stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $6.75, for a total transaction of $648,924.75. Following the completion of the sale, the insider now directly owns 1,554,103 shares of the company's stock, valued at $10,490,195.25. The trade was a 5.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.

Lifecore Biomedical Stock Performance

Shares of NASDAQ:LFCR traded down $0.24 during trading on Friday, reaching $6.61. 179,835 shares of the company's stock traded hands, compared to its average volume of 240,935. Lifecore Biomedical, Inc. has a 12 month low of $3.68 and a 12 month high of $7.99. The company has a debt-to-equity ratio of 9.21, a current ratio of 2.32 and a quick ratio of 1.21. The stock has a market capitalization of $244.74 million, a P/E ratio of -11.80 and a beta of 0.65. The company has a 50 day moving average of $6.52 and a 200-day moving average of $6.57.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last posted its earnings results on Thursday, April 3rd. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.05). Lifecore Biomedical had a negative return on equity of 315.23% and a negative net margin of 12.52%. The firm had revenue of $35.15 million during the quarter, compared to the consensus estimate of $33.23 million. On average, equities analysts expect that Lifecore Biomedical, Inc. will post -0.91 EPS for the current year.

Wall Street Analyst Weigh In

Separately, William Blair started coverage on shares of Lifecore Biomedical in a research report on Wednesday, May 21st. They set an "outperform" rating for the company.

Institutional Trading of Lifecore Biomedical

Institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC lifted its stake in shares of Lifecore Biomedical by 1,839.7% in the 1st quarter. GAMMA Investing LLC now owns 3,569 shares of the company's stock worth $25,000 after acquiring an additional 3,385 shares during the period. Summit Securities Group LLC acquired a new stake in shares of Lifecore Biomedical in the 1st quarter worth approximately $26,000. Hurley Capital LLC acquired a new stake in shares of Lifecore Biomedical in the 1st quarter worth approximately $35,000. Prudential Financial Inc. acquired a new stake in shares of Lifecore Biomedical in the 4th quarter worth approximately $95,000. Finally, Wells Fargo & Company MN lifted its stake in shares of Lifecore Biomedical by 29.0% in the 4th quarter. Wells Fargo & Company MN now owns 13,381 shares of the company's stock worth $99,000 after acquiring an additional 3,012 shares during the period. 83.36% of the stock is owned by institutional investors and hedge funds.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.